Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2018 1
2019 2
2020 1
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes DB, Patnaik A. Chaudagar K, et al. Among authors: swarbrick a. Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350. Clin Cancer Res. 2023. PMID: 36862086 Free PMC article.
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. Hickey TE, et al. Among authors: swarbrick a. Nat Med. 2021 Feb;27(2):310-320. doi: 10.1038/s41591-020-01168-7. Epub 2021 Jan 18. Nat Med. 2021. PMID: 33462444
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ, Lim Kam Sian TCC, Nguyen EV, Shin SY, Yang J, Hui MN, Deng N, McLean CA, Welm AL, Lim E, Gregory P, Nottle T, Lang T, Vereker M, Richardson G, Kerr G, Micati D, Jardé T, Abud HE, Lee RS, Swarbrick A, Daly RJ. Chew NJ, et al. Among authors: swarbrick a. Breast Cancer Res. 2021 Aug 3;23(1):82. doi: 10.1186/s13058-021-01461-4. Breast Cancer Res. 2021. PMID: 34344433 Free PMC article.
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.
Meyer B, Clifton S, Locke W, Luu PL, Du Q, Lam D, Armstrong NJ, Kumar B, Deng N, Harvey K, Swarbrick A, Ganju V, Clark SJ, Pidsley R, Stirzaker C. Meyer B, et al. Among authors: swarbrick a. Clin Epigenetics. 2021 Dec 18;13(1):226. doi: 10.1186/s13148-021-01210-6. Clin Epigenetics. 2021. PMID: 34922619 Free PMC article.
A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes.
Papachristou EK, Kishore K, Holding AN, Harvey K, Roumeliotis TI, Chilamakuri CSR, Omarjee S, Chia KM, Swarbrick A, Lim E, Markowetz F, Eldridge M, Siersbaek R, D'Santos CS, Carroll JS. Papachristou EK, et al. Among authors: swarbrick a. Nat Commun. 2018 Jun 13;9(1):2311. doi: 10.1038/s41467-018-04619-5. Nat Commun. 2018. PMID: 29899353 Free PMC article.
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ, Gauthier MA, Chan CL, Thompson TJ, De Sousa SMC, Puttick C, Grady JP, Gayevskiy V, Tao J, Ying K, Cipponi A, Deng N, Swarbrick A, Thomas ML, Lord RV, Johns AL, Kohonen-Corish M, O'Toole SA, Clark J, Mueller SA, Gupta R, McCormack AI, Dinger ME, Cowley MJ; kConFab. McCabe MJ, et al. Among authors: swarbrick a. Sci Rep. 2019 Nov 19;9(1):17052. doi: 10.1038/s41598-019-52000-3. Sci Rep. 2019. PMID: 31745186 Free PMC article.
Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.
Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS. Brockwell NK, et al. Among authors: swarbrick a. NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019. NPJ Precis Oncol. 2019. PMID: 31482136 Free PMC article.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E. Portman N, et al. Among authors: swarbrick a. Breast Cancer Res. 2020 Aug 12;22(1):87. doi: 10.1186/s13058-020-01318-2. Breast Cancer Res. 2020. PMID: 32787886 Free PMC article.
11 results